Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Blueprint Medicines ( (BPMC) ).
On June 2, 2025, Blueprint Medicines Corporation entered into a merger agreement with Sanofi, under which Sanofi will acquire Blueprint for approximately $9.1 billion in cash, with additional contingent value rights potentially increasing the total value to $9.5 billion. This acquisition is expected to enhance Sanofi’s portfolio in rare immunological diseases by adding Blueprint’s approved medicine for systemic mastocytosis and its early-stage immunology pipeline, thereby strengthening Sanofi’s position in the immunology sector.
The most recent analyst rating on (BPMC) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Blueprint Medicines stock, see the BPMC Stock Forecast page.
Spark’s Take on BPMC Stock
According to Spark, TipRanks’ AI Analyst, BPMC is a Neutral.
Blueprint Medicines demonstrates strong revenue growth and positive momentum in technical indicators. However, ongoing profitability challenges, a negative P/E ratio, and potential overbought conditions temper the outlook. Raised guidance and pipeline success are positives, but international market challenges persist.
To see Spark’s full report on BPMC stock, click here.
More about Blueprint Medicines
Blueprint Medicines Corporation is a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases. The company offers Ayvakit/Ayvakyt (avapritinib), a medicine approved in the US and EU for advanced and indolent systemic mastocytosis, and has a promising pipeline in immunology.
Average Trading Volume: 988,296
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.55B
See more insights into BPMC stock on TipRanks’ Stock Analysis page.